|
|
|
| Comparison of efficacy and prognosis of Roxadustat Capsules and recombinant human erythropoietin in the treatment renal anemia |
| LI Hongbin1 LIANG Jun1 MA Qiang2▲ |
1.Department of Nephrology, Beijing East District First People′s Hospital, Beijing 100075, China;
2.Department of Nephrology, the Second Medical Center of Chinese PLA General Hospital, Beijing 100853, China |
|
|
|
Abstract Objective To investigate the efficacy and prognosis of Roxadustat Capsules and recombinant human erythropoietin (rhEPO) in the treatment of maintenance hemodialysis (MHD) with renal anemia. Methods A total of 56 cases with MHD renal anemia who admitted to Beijing East District First People′s Hospital from July to October 2019 were selected as the subjects. They were divided into control group and study group by random number table method, with 28 cases in each group. Two groups were treated with Ferrous Succinate Tablets orally, and control group was treated with rhEPO, while study group was treated with Roxadustat Capsules. They were treated for 3 months. Anemia indicators [red blood cell count (RBC), hemoglobin (Hb), hematocrit (Hct)] and iron metabolism indexes [serum ferritin (SF), transferrin saturation (TSAT), transferrin (TRF), hepcidin (Hepc)] were compared between two groups before and after 3 months of treatment, and the adverse reactions were recorded. Results There was no significant difference in the levels of RBC, Hb and Hct between two groups before treatment（P > 0.05）；after 3 months of treatment, the levels of RBC, Hb, Hct were significantly higer than those before treatment, and study group was higher than control group, and the differences were statistically significant（all P < 0.05）. There was no significant difference in the levels of SF, TSAT, TRF and Hepc between two groups before treatment（P > 0.05）. After 3 months of treatment, the levels of SF, TSAT an TRF were significantly higer than those before treatment, the levels of Hepc were lower than those before treatment. The levels of SF, TSAT and TRF in study group were significantly higer than those in control group, the levels of Hepc in study group were lower than those in control group, and the differences were statistically significant（all P < 0.05）. The adverse reactions in study group were lower than those in control group, and the differences were statistically significant（P < 0.05）. Conclusion Compared with rhEPO, Roxadustat Capsules has better efficacy in the treatment of patients with MHD renal anemia, and it can significantly correct the symptoms of anemia, increase the utilization rate of iron in the body, and has higher safety and application value.
|
|
|
|
|
|
[1] 白荷荷，聂晓静，王园姬.297例重组人促红素及铁剂治疗血液透析肾性贫血的合理性评价[J].药物流行病学杂志，2018，27（6）：392-395.
[2] 林攀，丁小强，袁敏，等.慢性肾脏病患者贫血患病现况调查[J].复旦学报：医学版，2009，36（5）：562-565.
[3] 张馨文，刘雯玥，肖桂芝，等.低氧诱导因子脯氨酰羟化酶抑制剂roxadustat[J].现代药物与临床，2016，31（4）：551-556.
[4] 中国医师协会肾内科医师分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识（2014修订版）[J].中国肾脏病杂志，2014，30（9）：712-716.
[5] 中华医学会肾脏病学分会.重组人促红细胞生成素在肾性贫血中合理应用的专家共识[J].中国血液净化，2007， 6（8）：440-443.
[6] Besarab A，Provenzano R，Hertel J，et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat（FG-4592）to treat anemia in nondialysis-dependent chronic kidney disease（NDD-CKD）patients [J]. Nephrol Dial Transplant，2015，30（10）：1665-1673.
[7] 林善琰.慢性肾脏病贫血[M].北京：中国协和医科大学出版社，2019：143-144.
[8] 姜涵文，何敬东.维持性血透患者PTH水平对肾性贫血的影响[J].中外医学研究，2018，16（27）：139-140.
[9] Ma JZ，Ebben J，Xia H，et al. Hematocrit level and associated mortality in hemodialysis patients [J]. J Am Soc Nephrol，1999，10（3）：610-619.
[11] 吴韵华，陆焕俊，王健生.蔗糖铁联合重组人促红素注射液治疗血液透析患者肾性贫血的疗效观察[J].贵州医药，2018，42（10）：1188-1189.
[11] 李雪梅，吕彬，金巧玲，等.多糖铁复合物口服与蔗糖铁注射治疗肾性贫血的疗效及不良反应对比[J].中国现代医生，2019，57（8）：37-39.
[12] 王莉莉，钟丽，覃献策.蔗糖铁注射液联合重组人红细胞生成素治疗血液透析肾性贫血对患者生存质量的影响[J].中国医药科学，2018，8（22）：25-27，53.
[13] 朱思梅，杨汉跃，王建涛.低氧诱导因子脯氨酰羟化酶抑制剂治疗肾性贫血的研究进展[J].中国新药杂志，2017， 26（22）：2701-2705.
[14] Li Z，You Q，Zhang X. Small-Molecule Modulators of the Hypoxia-Inducible Factor Pathway：Development and Therapeutic Applications [J]. J Med Chem，2019，62（12）：5725-5749.
[15] Joharapurkar AA，Pandya VB. Prolyl Hydroxylase Inhibitors：A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases [J]. J Med Chem，2018， 61（16）：6964-6982.
[16] 贺晓瑛，潘兴泉，李家国，等.治疗肾性贫血新药-roxadustat[J].临床药物治疗杂志，2018，16（8）：1-3，8.
[17] Dorien GVDM，Den AM，Jan N，et al. Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat，an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor [J]. Clin Drug Invest，2016，36（9）：743-751.
[18] Chen N，Qian J，Chen J，et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China [J]. Nephrol Dial Transplant，2017，32（8）：1373-1386.
[19] Chen N，Hao C，Peng X，et al. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis [J]. N Engl J Med，2019，381（11）：1001-1010.
[20] Provenzano R，Besarab A，Sun CH，et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat（FG-4592）for the treatment of anemia in patients with CKD [J]. Clin J Am Soc Nephrol，2016，11（6）：982-991.
[21] 常园园，范秋灵.Erythroferrone-铁调素轴在肾性贫血中的研究进展[J].中国临床研究，2017，30（2）：268-271.
[22] 李月琼，刘雨田，吕德.重组人促红素联合多糖铁治疗血液透析后肾性贫血[J].深圳中西医结合杂志，2018， 28（22）：156-157.
[23] Chen N，Hao C，Liu BC，et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis [J]. N Engl J Med，2019，381（11）：1011-1022.
[24] 周雅萍，李凯.治疗肾性贫血新药罗沙司他[J].药物评价研究，2018，41（9）：1743-1748. |
|
|
|
